{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-319156","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.497087+00:00","generated_at":"2026-05-16T13:12:15.574366+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silence Therapeutics CEO Craig Tooman departs by mutual consent; Chairman Iain Ross named interim CEO","bullets":["Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.","Chairman Iain Ross appointed as interim principal executive officer effective immediately.","James Ede-Golightly re-appointed to Board; previously served as Non-Executive Director from 2019 to June 2025.","Company expects to add a US-based Board member in due course."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-319156","json":"https://secwatch.observer/filing/0001193125-25-319156.json","markdown":"https://secwatch.observer/filing/0001193125-25-319156.md","text":"https://secwatch.observer/filing/0001193125-25-319156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/0001193125-25-319156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/sln-20251214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:12:15.574366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}